Literature DB >> 24037549

Interferon-α abrogates the suppressive effect of apoptotic cells on dendritic cells in an in vitro model of systemic lupus erythematosus pathogenesis.

Lucie Abeler-Dörner1, Cosima C Rieger, Bartlomiej Berger, Heiko Weyd, Daniela Gräf, Sandra Pfrang, Ingo H Tarner, Andreas Schwarting, Hanns-Martin Lorenz, Ulf Müller-Ladner, Peter H Krammer, Annegret Kuhn.   

Abstract

OBJECTIVE: An increased incidence of apoptotic cells and an increased activation of dendritic cells (DC) may be involved in the pathogenesis of systemic lupus erythematosus (SLE). We investigated the characteristics of apoptotic neutrophils and monocyte-derived DC of patients with SLE, their interaction, and the influence of autoantibodies and inflammatory cytokines on this interaction.
METHODS: Kinetics of neutrophil apoptosis and DC activation were studied by flow cytometry. To analyze the interaction of apoptotic cells with phagocytes, crossover coculture experiments were performed with DC from patients with SLE and apoptotic Jurkat T cells as well as with apoptotic neutrophils from patients with SLE and the monocytic cell line U937. SLE serum and cytokines were added to this coculture, and activation and suppression of DC were quantified by levels of inflammatory cytokine secretion.
RESULTS: Apoptotic neutrophils and DC from patients with SLE showed no inherent defects compared to healthy controls, and the suppressive nature of their interaction was not affected. Autoantibodies as well as the inflammatory cytokines interleukin 17 (IL-17) and IL-1β had no influence on the interaction in this setup. Interferon (IFN)-α, however, substantially reduced the suppressive effect of apoptotic cells on DC.
CONCLUSION: The data suggest that aberrant immune reactivity in SLE is not generally due to an intrinsic defect in apoptotic cells, their processing, or their interaction with DC, but likely arises from the milieu in which this interaction takes place. Our study highlights the importance of IFN-α during early stages of SLE and its potential as a therapeutic target.

Entities:  

Keywords:  ANNEXIN A1; APOPTOSIS; AUTOIMMUNE DISEASES; DENDRITIC CELLS; INTERFERON-α; SYSTEMIC LUPUS ERYTHEMATOSUS

Mesh:

Substances:

Year:  2013        PMID: 24037549     DOI: 10.3899/jrheum.121299

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

Review 1.  Contribution of dendritic cells to the autoimmune pathology of systemic lupus erythematosus.

Authors:  Juan P Mackern-Oberti; Carolina Llanos; Claudia A Riedel; Susan M Bueno; Alexis M Kalergis
Journal:  Immunology       Date:  2015-10-12       Impact factor: 7.397

Review 2.  Advances in understanding the role of type I interferons in systemic lupus erythematosus.

Authors:  Mary K Crow
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

Review 3.  Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review.

Authors:  Annegret Kuhn; Jörg Wenzel; Heiko Weyd
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 10.817

4.  Lupus nephritis with corticosteroid responsiveness: molecular changes of CD46-mediated type 1 regulatory T cells.

Authors:  Jien-Wen Chien; Ying-Ming Chiu; Yi-Giien Tsai; Tzu-Cheng Su; Ping-Fang Chiu; Kai-Hung Hsiao; Ching-Yuang Lin
Journal:  Pediatr Res       Date:  2021-12-24       Impact factor: 3.953

5.  Targeting Thioredoxin-1 by dimethyl fumarate induces ripoptosome-mediated cell death.

Authors:  Anne Schroeder; Uwe Warnken; Daniel Röth; Karel D Klika; Diana Vobis; Andrea Barnert; Fatmire Bujupi; Tina Oberacker; Martina Schnölzer; Jan P Nicolay; Peter H Krammer; Karsten Gülow
Journal:  Sci Rep       Date:  2017-02-24       Impact factor: 4.379

Review 6.  Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications.

Authors:  Jitka Fucikova; Lenka Palova-Jelinkova; Jirina Bartunkova; Radek Spisek
Journal:  Front Immunol       Date:  2019-10-29       Impact factor: 7.561

7.  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Authors:  Munther Khamashta; Joan T Merrill; Victoria P Werth; Richard Furie; Kenneth Kalunian; Gabor G Illei; Jorn Drappa; Liangwei Wang; Warren Greth
Journal:  Ann Rheum Dis       Date:  2016-03-23       Impact factor: 19.103

Review 8.  Breakdown of Immune Tolerance in Systemic Lupus Erythematosus by Dendritic Cells.

Authors:  Xiaofeng Liao; Alec M Reihl; Xin M Luo
Journal:  J Immunol Res       Date:  2016-02-29       Impact factor: 4.818

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.